Highest-materiality recent filing
Plus Therapeutics enters into $17.35M ATM equity distribution agreement with Canaccord Genuity
Up to $17.35M of common stock may be sold at-the-market through Canaccord Genuity as agent.
Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation
Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.
Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant
Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.
Plus Therapeutics' REYOBIQ gets FDA Orphan Drug Designation for pediatric malignant gliomas
ODD covers pediatric malignant gliomas including ependymoma, broader than originally requested.
Plus Therapeutics Approves FY2025 Cash Bonuses: CEO Hedrick Gets $305,663, CFO Sims Gets $149,175
On Feb 9, 2026, Compensation Committee approved discretionary cash bonuses for Named Executive Officers for FY2025.
Plus Therapeutics prices $15M public offering of 39.5M units at $0.38; net ~$13.3M
Offering of 39,473,684 units at $0.38 each, each unit = one share + one warrant.
Plus Therapeutics gets Nasdaq extension until May 11, 2026 to regain $1 bid price
Received 180-day extension to May 11, 2026 from Nasdaq to meet $1.00 minimum bid price rule.
Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances
Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.
Lease covers 11,370 rentable square feet on third floor of 6420 Levit Green Blvd, Houston; 120-month term.
Nasdaq confirmed compliance with MVLS ($35M) and equity ($2.5M) standards on Aug 22, 2025.
Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas
Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.
Plus Therapeutics Regains Nasdaq Compliance; Reports $3M Stockholders' Equity and $35M+ MVLS
Reported stockholders' equity of $3M as of June 30, 2025, satisfying Nasdaq's minimum $2.5M Equity Rule.
Plus Therapeutics updates Nasdaq listing; panel grants continued listing with conditions
Nasdaq panel granted continued listing; must demonstrate $2.5M stockholders' equity compliance by Aug 14, 2025.
All six director nominees were elected to the board for a term expiring at the 2026 annual meeting.
Plus Therapeutics enters $50M common stock purchase agreement with Lincoln Park Capital
Plus Therapeutics signed a purchase agreement with Lincoln Park Capital for up to $50 million of common stock over 36 months.
Plus Therapeutics cuts Series B warrant shares from 1.26B to 35.5M; cancels Series A warrants
Cancelled all Series A warrants exercisable for up to 280M shares of common stock.
Plus Therapeutics gets Nasdaq delisting notice for negative stockholders' equity
Company reported stockholders' equity deficit of $23.6M as of March 31, 2025, failing Nasdaq's $2.5M minimum.
Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants
Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.
Plus Therapeutics receives Nasdaq deficiency notice for late Q1 10-Q filing
Received Nasdaq notice on May 21, 2025 for missing Q1 2025 Form 10-Q filing deadline.
Plus Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Plus Therapeutics on May 16, 2025 of non-compliance with minimum bid price rule (closing bid < $1.00 for 30 consecutive days).
Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.
Plus Therapeutics regains Nasdaq minimum equity compliance after private placement
Received Nasdaq letter dated March 7, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
Plus Therapeutics raises $15M in private placement; exchanges $3.2M in convertible notes
Private placement of ~28M shares (or prefunded warrants) at $0.66/unit, each with Series A and B warrants.
Issued $3.36M in secured convertible notes and warrants to purchase ~3M shares at $1.12; aggregate proceeds ~$3.7M.
Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial
Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.
Plus Therapeutics receives Nasdaq extension until March 4, 2025 to regain minimum equity compliance
Nasdaq Hearings Panel granted extension to March 4, 2025 for Plus Therapeutics to meet $2.5M stockholders' equity minimum.
Plus Therapeutics receives Nasdaq delisting notice; plans appeal to stay listing
Nasdaq notified on Sept 5, 2024 that company failed to regain compliance with minimum $2.5M stockholders' equity rule.
Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M
ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.
Plus Therapeutics draws $3.3M from Pershing facility to repay Oxford term loan in full
Drew $3.3M from Pershing margin loan facility at FOMC target (floor 5.5%) + 1.75% spread + 0.5% fees, max Prime+3%.
Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing
Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.
PSTV raises $7.25M via private placement of shares and warrants
Gross proceeds of $7.25M from private placement of 3,591,532 units at $2.022/$2.158 per unit.
Plus Therapeutics receives Nasdaq delisting notice for equity deficiency
Stockholders' equity was ($1,348,000) as of Dec 31, 2023, below Nasdaq's $2.5M minimum.
Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5
Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.
Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo
Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).
On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately.
On June 5, 2024, Plus Therapeutics, Inc. (the “Company”) received the resignation of Dr. Norman LaFrance, its Chief Medical Officer.
On September 13, 2021, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer (“CMO”) and Senior Vice President of the Company, effective on or around December 8, 2021.
Max materiality 0.95 · Median 0.65 · Most common event other_material